drug
rotavirus [serotypes G1, G2, G3, G4, P1] (pentavalent) vaccine
Marketedupdated 3mo agoby $MRK Merck & Co., Inc.
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying rotavirus [serotypes G1, G2, G3, G4, P1] (pentavalent) vaccine
- phase3Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
- phase3Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
- phase3Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
- phase3Immunogenicity and Safety of Concomitant and Non-Concomitant Administration of RotaTeq® (V260) and Inactivated Poliomyelitis Vaccine in Healthy Chinese Infants (V260-074)
- phase3Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that